Skip Navigation


Annals of Oncology Advance Access originally published online on November 20, 2007
Annals of Oncology 2007 18(12):2042-2043; doi:10.1093/annonc/mdm504
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
18/12/2042    most recent
mdm504v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Chen, J.-H.
Right arrow Articles by Su, M.-Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, J.-H.
Right arrow Articles by Su, M.-Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

letters to the editor

Triple-negative breast cancer: MRI features in 29 patients

The first 10% of the full text of this article appears below.

Triple-negative (TN) breast cancers were defined as those which tested negative for estrogen receptor (ER), progesterone receptor (PR), and HER2. TN breast cancers account for 12%–26% of all types of breast cancers [1–5]. TN tumors were aggressive and were usually diagnosed at a later stage [5]. About 85% of TN phenotypic breast cancers are deemed to be basal like and have a clinical behavior similar to basal-like tumors [2]. The most common histological types for TN breast cancer were invasive ductal carcinomas and metaplastic carcinomas [2]. Histologically, TN cancers are poorly differentiated, . . . [Full Text of this Article]

funding

J.-H. Chen1,2,*, G. Agrawal1, B. Feig1, H.-M. Baek1, P. M. Carpenter3, R. S. Mehta, O. Nalcioglu1 and M.-Y. Su1

1 Center for Functional Onco-Imaging, University of California, Irvine, CA, USA
2 Department of Radiology, China Medical University Hospital, Taichung, Taiwan
3 Department of Pathology and Laboratory Medicine
4 Department of Medicine, University of California, Irvine, CA, USA

* (E-mail: jeonhc@uci.edu)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
S. Bahri, J.-H. Chen, H. J. Yu, A. Kuzucan, O. Nalcioglu, and M.-Y. Su
Can dynamic contrast-enhanced MRI (DCE-MRI) predict tumor recurrence and lymph node status in patients with breast cancer?
Ann. Onc., April 1, 2008; 19(4): 822 - 824.
[Full Text] [PDF]